Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Male Reproductive SystemDRG 714-transurethral-prostatectomy-without-cc-mcc
    Ask Trek AI about this page

    Transurethral Prostatectomy without CC/MCC: Inpatient Reimbursement Overview

    DRG 714 addresses inpatient admissions for transurethral prostatectomy performed without a Complication or Comorbidity or Major Complication or Comorbidity, covering straightforward surgical management of obstructive prostatic conditions. This group matters for inpatient reimbursement because it defines a bundled payment level under Medicare that is sensitive to procedure coding and documented secondary diagnoses.

    Customize your policy alerts

    Sign up for drg 714 policy alerts

    Get alerted when payer policies referencing 714 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 714 Overview

    DRG 714 covers inpatient hospital admissions for transurethral prostatectomy procedures performed without a Complication or Comorbidity or Major Complication or Comorbidity. This Diagnosis-Related Group captures cases typically involving surgically managed benign prostatic hyperplasia or similar obstructive lower urinary tract conditions where no significant secondary diagnoses increase resource use. DRG 714 matters for Medicare payment because it groups these straightforward surgical admissions into a defined payment bundle that influences hospital reimbursement and care planning. Accurate coding of procedures and comorbidities determines assignment to this Diagnosis-Related Group and the associated inpatient payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials evaluating perioperative techniques and anesthesia protocols for transurethral prostatectomy: studies compare spinal versus general anesthesia approaches, variations in irrigation solutions, or hemostatic agents used during resection to reduce intraoperative bleeding and TUR syndrome. The patient population includes men undergoing transurethral prostatectomy for benign prostatic hyperplasia (BPH) without major complications, often older adults with common comorbidities (e.g., hypertension, anticoagulant use). These studies are relevant because optimizing intraoperative management can shorten operative time, reduce immediate complications and transfusion needs, and influence length of stay and cost for hospitals and payers.
    • Comparative effectiveness trials of surgical techniques and energy modalities for lower urinary tract obstruction: randomized or observational studies compare standard monopolar resection with bipolar resection, laser enucleation or vaporization methods, and variations in enucleation versus simple resection for men with moderate-to-large prostates. Participants are men selected for endoscopic prostatic surgery where the research question is which technique yields better symptom relief, lower catheterization time, and fewer readmissions or reoperations in the 30–90 day postoperative window. Findings inform providers and payers about relative clinical outcomes, resource utilization, device or equipment needs, and potential differences in complication rates that affect reimbursement and bundle payments.
    • Post-discharge outcomes and care pathway studies focused on recovery, complications, and health services use: prospective cohort or registry-based research tracks readmission rates, urinary retention, urinary tract infection, erectile or continence outcomes, and outpatient follow-up patterns in patients after transurethral prostatectomy. The studied population includes typical inpatient cases without major complications at index admission, monitored across the immediate 30–90 day post-discharge period to identify predictors of adverse events and high-cost utilization. This research helps payers and health systems design post-acute care pathways, targeted education, and surveillance to reduce avoidable readmissions and downstream costs while maintaining quality metrics.

    Related Codes

    707-MAJOR-MALE-PELVIC-PROCEDURES-WITH-CC-MCC

    Major Male Pelvic Procedures with CC/MCC: Inpatient Reimbursement Overview

    708-MAJOR-MALE-PELVIC-PROCEDURES-WITHOUT-CC-MCC

    Major Male Pelvic Procedures without CC/MCC: Inpatient Reimbursement Overview

    709-PENIS-PROCEDURES-WITH-CC-MCC

    Penis Procedures with CC/MCC: Inpatient Reimbursement Overview

    710-PENIS-PROCEDURES-WITHOUT-CC-MCC

    Penis Procedures without CC/MCC: Inpatient Reimbursement Overview

    711-TESTES-PROCEDURES-WITH-CC-MCC

    Testes Procedures with CC/MCC: Inpatient Reimbursement Overview

    712-TESTES-PROCEDURES-WITHOUT-CC-MCC

    Testes Procedures without CC/MCC: Inpatient Reimbursement Overview

    713-TRANSURETHRAL-PROSTATECTOMY-WITH-CC-MCC

    Transurethral Prostatectomy with CC/MCC: Inpatient Reimbursement Overview

    715-OTHER-MALE-REPRODUCTIVE-SYSTEM-O-R-PROCEDURES-FOR-MALIGNANCY-WITH-CC-MCC

    Other Male Reproductive System O.R. Procedures for Malignancy with CC/MCC: Inpatient Reimbursement Overview

    716-OTHER-MALE-REPRODUCTIVE-SYSTEM-O-R-PROCEDURES-FOR-MALIGNANCY-WITHOUT-CC-MCC

    Other Male Reproductive System O.R. Procedures for Malignancy without CC/MCC: Inpatient Reimbursement Overview

    717-OTHER-MALE-REPRODUCTIVE-SYSTEM-O-R-PROCEDURES-EXCEPT-MALIGNANCY-WITH-CC-MCC

    Other Male Reproductive System O.R. Procedures Except Malignancy with CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 20

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.